[The effect of ethylenediaminetetramethylenephosphonate on the biodistribution of tumor-seeking radionuclides].
It is well known that after application of radioactive complexes for tumour diagnosis or therapy, such as 67Ga-citrate or radiolanthanide complexes (167Tm- or 169Yb-nitrilotriacetate, -citrate, -alpha-hydroxyisobutyrate, 90Y-citrate, etc.) activity is accumulated not only in the tumour but also in other organs, above all liver and bone. This is the main obstacle to their medical use. Recently published results encouraged us to use ethylenediaminetetramethylene phosphonate (EDTMP) for the reduction of extratumoural liver activity. The results show that even small amounts of EDTMP (1-2 mg/kg BW) reduce the activity deposition in the liver by about one order of magnitude. EDTMP provoked elimination of activity from tumour, skeleton and other tissues but not to the same extent as from the liver. Tumor/liver activity ratios > 5 are achievable in this manner.
Schomäcker
K
K
Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln.
Franke
W G
WG
Mäding
P
P
Shukla
S K
SK
Weiss
S
S
Limouris
G S
GS
Jantsch
K
K
D000818:Animals; D001842:Bone and Bones / Q000378:metabolism*; D002614:Chelating Agents / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism*; D008297:Male; D008546:Melanoma, Experimental / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000532:radiotherapy; D051379:Mice; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D011868:Radioisotopes / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011877:Radionuclide Imaging; D015018:Ytterbium / Q000493:pharmacokinetics* / Q000627:therapeutic use
D002614:Chelating Agents; D009943:Organophosphorus Compounds; D011868:Radioisotopes; C018940:(ethylenedinitrilo)-tetramethylenephosphonic acid; D015018:Ytterbium
Der Einfluss von Ethylendiamintetramethylenphosphonat auf die Bioverteilung tumoraffiner Radionuklide.